SL-145 is a C-terminal heat shock protein 90 (HSP90) inhibitor. SL-145 elicits anti-tumor and anti-metastatic effects without triggering the heat shock response (HSR) due to its unconventional targeting of the C-terminal region. SL-145 simultaneously inhibits multiple oncogenic signaling pathways including AKT, MEK/ERK, and JAK2/STAT3 in vitro and in vivo.

KEYWORDS: SL-145 | Supplier | HSP90 inhibitor | SL145 | SL 145 | CAS [2051587-62-1] | Unfolded protein response (Non selective) | Hsp90 | Inhibitor | Enzymes | Heat shock protein 90 | Metastatic triple-negative breast cancer | TNBC | Antiangiogenic